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ABSTRACT 
Purpose: Patients with MS often experience OABS. High dose BoNT/A intradetrusor treatment is 
effective but often results in urinary retention and urinary diversion via a catheter. In this pilot study we 
evaluated whether only 100 units onabotulinumtoxinA would significantly decrease OABS in patients 
with MS without impairing pre-treatment voluntary voiding. 
 
Materials and Methods: Included in our study were 12 patients with MS who had OABS such as 
urgency, frequency and / or urgency incontinence. The treatment effect was evaluated using data on 3 
consecutive visits, that is before, and a mean ± SD of 46.2 ± 11.9 and 101 ± 21 days after 
intradetrusor injection of 100 units Botox®, including the results of cystometry and uroflowmetry at 
visits 1 and 2, and uroflowmetry alone at visit 3. Patients completed a 3-day voiding diary for all 3 
visits. 
 
Results: Maximum bladder capacity significantly increased and maximum detrusor pressure 
decreased. Daytime and nighttime frequency, urgency and pad use significantly decreased. PVRV 
significantly increased initially but decreased until 12 weeks. Median time to re-injection due to 
recurrent overactive bladder symptoms was 8 months. 
 
Conclusions: Overactive bladder treatment in patients with MS using 100 units OnabotulinumtoxinA 
intradetrusor injections seems to be effective and safe. Despite slightly impaired detrusor contractility 
most patients still voided voluntarily without symptoms. Thus, 100 units OnabotulinumtoxinA may be a 
reasonable treatment option for OABS in patients with MS who still void voluntarily. 
 
Key words: urinary bladder; overactive bladder; multiple sclerosis; botulinum toxin A; urination 
disorders 
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INTRODUCTION 
LUTD is common in patients with MS and can severely impair QoL in addition to the restrictions 
already experienced due to the neurological disease [1-4]. Of the patients 10% are already affected by 
detrusor and sphincter disorders at the initial MS diagnosis [1]. Initial symptoms of LUTD are often 
irritative, such as urgency and frequency, but incontinence or urinary retention also occurs often [1]. In 
the MS course the prevalence and severity of these symptoms inevitably increase and up to 75% of 
patients with MS experience bladder problems during the disease course [3-5]. A point is commonly 
reached at which patients with MS do not tolerate first line antimuscarinic treatment or find the effects 
insufficient to treat OABS and second line treatment becomes necessary [6]. 
BoNT/A is an effective second line treatment for OABS in neurogenic cases. Most often a dose of 300 
units is chosen when using OnabotulinumtoxinA for intradetrusor injection [7]. However, patients with 
MS often present with initial PVRV and treating them with 300 units OnabotulinumtoxinA may probably 
result in high PVRV or urinary retention, requiring ISC or an indwelling catheter [1, 6-8]. This is often 
not satisfactory in patients with MS who are still ambulatory and voluntarily empty most of the bladder 
capacity. 
Recently 100 units OnabotulinumtoxinA were noted to effectively alleviate OABS in non-neurogenic 
cases without causing urinary retention or a significant increase in PVRV [9, 10]. To our knowledge 
there is as yet no proof that 300 units OnabotulinumtoxinA are needed to efficiently treat OABS in MS 
cases. Drug treatment usually starts with a low dose that can be increased as needed, rather than with 
a high dose. 
The aims of our study were to (1) investigate whether intradetrusor injections of only 100 units 
OnabotulinumtoxinA would sufficiently treat OABS in patients with MS and 2) observe whether 100 
units OnabotulinumtoxinA would prevent urinary retention and, thus, provide the possibility of avoiding 
or decreasing the frequency of de novo ISC. We hypothesized that 100 units OnabotulinumtoxinA 
would alleviate OABS in our MS population but efficient, symptom-free voluntary voiding would still be 
possible. 
 
MATERIALS AND METHODS 
After receiving approval from the local ethics committee we recruited patients with MS who consulted 
our neuro-urology department for treatment of LUTS. Study inclusion criteria were a proven diagnosis 
of MS; OABS with or without incontinence, as documented by 3-day voiding diary, with at least 3 
urgency episodes in 3 days that were refractory to at least 2 antimuscarinic agents, each ingested for 
1 month; treatment naïve status to BoNT/A before the first consultation at our department; preserved 
voluntary voiding or voluntary voiding as the only way of bladder emptying; ability and willingness to 
perform ISC; and written informed consent. Study exclusion criteria were neurological diseases other 
than MS, MS relapse 6 months before or during the evaluation period, previous LUT surgery or 
malignancy and previous BoNT/A treatment. 
Mehnert U Effect of botulinum toxin type A on OAB symptoms in patients with multiple sclerosis J Urol 2010 
 
 
 
Figure 1 Study course 
 
All patients had to complete 5 visits, including initial urodynamic evaluation at visit 1, blood and urine 
test before BoNT/A intradetrusor injection at visit 2, Botox® intradetrusor injection at visit 3, post-
treatment urodynamic evaluation 6 to 7 weeks after injection at visit 4 and uroflowmetry follow-up 12 to 
14 weeks after injection at visit 5 (Figure 1). At visits 1, 4 and 5 a 3-day voiding diary was completed 
(Figure 1). 
BoNT/A intradetrusor injection at visit 3 was done with a 19Fr or 22Fr rigid cystoscope and a 22 gauge 
0.7 mm needle 8 mm long. Only half of the needle was inserted. Each patient received 100 units 
OnabotulinumtoxinA diluted in 10 ml 0.9% saline and distributed over 10 injection sites at 1 ml each. 
Local anesthesia of the bladder mucosa was achieved with 50 ml 2% lidocaine / 8.4% bicarbonate 
solution instilled into the bladder for 10 minutes before injection. 
Evaluated outcome parameters were maximum detrusor pressure (pDetmax), maximum cystometric 
capacity (MCC), bladder volume at first desire to void (FDV) on video cystometry at visits 1 and 4; 
voided volume, maximum flow rate (Qmax), PVRV on uroflowmetry at visits 1, 4 and 5; daytime and 
nighttime frequency, incontinence episodes, urgency episodes and number of pads used on voiding 
diary at visits 1, 4 and 5. All outcome parameters were defined according to the International 
Continence Society standardization of terminology [11]. 
We also assessed the extended disability symptom scale (EDSS) in all patients to provide information 
on individual impairment (Table 1) [12]. The EDSS range is 0.0—normal neurological examination to 
10.0—death from MS and it quantifies the disability in 8 functional systems. Procedure pain and 
patient satisfaction were evaluated using 2 visual analogue scales (VAS) with a range of 1—no pain or 
complete dissatisfaction to 10—worst pain or maximum satisfaction. 
Patients were eligible for re-injection on demand but not before 3 months after the previous injection. 
The reinjection appointment was scheduled by patients when OABS recurred. 
Video cystometry outcome parameters were statistically compared between visits 1 and 4 using the 
nonparametric Wilcoxon signed ranks test with α = 0.05. Uroflowmetry and voiding diary outcome 
parameters were statistically compared among visits 1, 4 and 5 using the nonparametric Wilcoxon 
signed ranks test but due to multiple comparisons α = 0.025. 
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Table 1 Patient demographics 
Patient No. - Gender Age [years] at BoNT/A injection Age [years] at MS diagnosis EDSS 
1 - F 43 35 3.0 
2 - F 58 41 3.0 
3 - F 60 45 4.5 
4 - F 39 27 5.5 
5 - F 50 20 6.0 
6 - F 62 29 6.0 
7 - F 51 34 7.5 
8 - M 50 33 6.0 
9 - F 43 37 4.5 
10 - F 65 35 3.0 
11 - F 59 52 6.0 
12 - F 38 21 4.5 
Mean ±SD 51.5 ±9.3 34.1 ±9.3 5.0 ±1.5 
BoNT/A botulinum neurotoxin A, EDSS extended disability symptom scale, MS multiple sclerosis 
 
RESULTS 
One man and 11 women with a mean ± SD age of 50.7 ± 10 years met all study inclusion and 
exclusion criteria, and were evaluated (Table 1). Mean time between visits 3 and 4 was 44.1 ± 10.6 
days and between visits 3 and 5 it was 113.8 ± 61.4 days. Before visit 2 no patient performed ISC. 
All patients showed OABS on 3-day voiding diary at visit 1, although some had normal video 
cystometry results. No patient had VUR before or after treatment. DO with incontinence was observed 
on cystometry in 7 patients before and in 3 after Botox® application. 
Mean MCC significantly increased in 9 patients from 352.6 ml at visit 1 to 538.8 ml at visit 4 (p = 
0.008). The remaining 3 patients already had an initial MCC of about 600 ml. However, comparison of 
all 12 MCCs between visits 1 and 4 revealed a significant increase (p = 0.034, Figure 2). Mean 
volume at FDV increased significantly from 340.3 ± 233 ml at visit 1 to 453.1 ± 200 ml at visit 4 (p = 
0.05). In all patients Pdetmax decreased significantly from a mean of 38.0 cmH2O at visit 1 to 16.3 
cmH2O at visit 4 (p = 0.004, Figure 3A). 
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Figure 2 Volume at FDV and MCC at visits 1 (open bars) and 4 (light gray bars), and voided 
volume and PVRV at visits 1, 4 and 5 (dark gray bars) in all patients. Box plots indicate 
minimum, 25% percentile, median, 75% percentile and maximum. Pound sign indicates p = 
0.05. Asterisk indicates p = 0.034. Plus sign indicates p = 0.003. 
 
Voiding diary data showed a significant decrease in frequency, urgency episodes and pad use from 
visits 1 to 4 (Table 2, Figure 4). This significant decrease was sustained up to visit 5 (Table 2, Figure 
4). We noted a significant decrease in nocturia from visits 1 to 4 (Table 2, Figure 4). However, this 
significant decrease was not sustained up to visit 5, although mean nighttime frequency was still lower 
at visit 5 than at visit 1 (Table 2). The mean number of incontinence episodes decreased continuously 
from visits 1 to 5 but we noted no significant difference between visits in the number of incontinence 
episodes (Table 2, Figure 4). 
We found no significant differences between visits in voided volume and Qmax, although each 
parameter seem to slightly decrease from visits 1 to 5 (Table 2, Figure 2, and Figure 3B). PVRV 
significantly increased from visits 1 to 4 (Table 2, Figure 2). However, until visit 5 PVRV decreased 
back toward baseline values and we noted no significant difference between visits 1 and 5 (Table 2, 
Figure 2). 
 
Mehnert U Effect of botulinum toxin type A on OAB symptoms in patients with multiple sclerosis J Urol 2010 
 
 
Figure 3 A, Pdet max during filling cystometry in all patients at visits 1 and 4. B, Qmax during 
uroflowmetry in all patients at visits 1, 4 and 5. ml/s, ml per second. Box plots indicate 
minimum, 25% percentile, median, 75% percentile and maximum. § indicates p = 0.004 
 
After visit 3 ISC was needed only in 2 patients once to twice daily on demand. One patient needed a 
suprapubic catheter. The need for ISC was based on symptoms, eg persistent OABS or recurrent UTI, 
and not related to a certain PVRV. The mean incidence of symptomatic UTI was 1.0 ± 1.1 at 12 
months before BoNT/A injection and 1.1 ± 1.4 between BoNT/A injection and re-injection. Other 
adverse events were mild self-limited hematuria in 6 patients and mild self-limited injection site pain in 
8. The mean VAS pain score in those cases was 2.8 ± 1.9 points. 
The mean VAS satisfaction score in all patients was 7.3 ± 2.1. Ten of 12 patients agreed to be treated 
with BoNT/A again. Of those 10 patients 1 was lost to further follow-up and 9 required re-injection after 
a mean of 11 ± 6.1 months (median 8, range 5 to 22). The 2 patients who did not agree to re-injection 
were not satisfied with the treatment outcome, although 1 showed significant improvement in the 
urodynamic and voiding diary parameters. 
 
Table 2 Three-day voiding diary and uroflowmetry results in 12 patients at visits 1, 4, and 5. 
  
Visit 1  
[mean ±SD] 
Visit 4  
[mean ±SD] 
p Value 
vs Visit 
1* 
Visit 5  
[mean 
±SD] 
p Value vs Visit 
1* 
No. voids 
Daytime 11.4 ±3.5 7.1 ±2.1 p = 0.002 8.5 ±2.6 p = 0.004 
Nighttime 2.4 ±1.4 1.3 ±1.2 p = 0.005 1.9 ±2.0 p = 0.107 
No. episodes / 
day 
Inconti-nence 3.8 ±5.1 1.9 ±3.2 p = 0.041 1.0 ±1.4 p = 0.214 
Urgency 9.1 ±5.7 2.8 ±3.8 p = 0.013 4.4 ±5.2 p = 0.008 
No. pads / day  1.9 ±09 0.8 ±0.8 p = 0.020 0.7 ±0.9 p = 0.011 
Uroflow-metry 
Voided vol. (mL) 337.4 ±256.5 330.8 ±186.2 p = 0.875 
221.3 
±132.4 
p = 0.239 
Qmax (mL/s) 27.9 ±21.0 23.1 ±13.2 p = 0.530 18.7 ±13.5 p = 0.055 
PVRV (mL)  98.3 ±77.6 222.1 ±113.2 p = 0.003 135.2 ±94.8 p = 0.328 
PVRV post void residual volume, *α = 0.025
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DISCUSSION 
Our study showed significant improvement in all cystometric and voiding diary parameters except 
incontinence episodes after intradetrusor injection of only 100 units OnabotulinumtoxinA. Currently 
only 2 studies are available of the effect of BoNT/A intradetrusor injections in a pure MS population 
and each describes the effect of 300 units [6, 13]. Direct comparison of the studies by Schulte- 
Baukloh [13] and Kalsi [6] with our study remains difficult and no direct conclusion can be drawn about 
which dose is more effective. However, somewhat similar results were observed in cystometric 
parameters at 4 to 6-week follow-up, and for voiding diaries at 4 to 6 and 12 to 16-week follow-up. 
Nevertheless, decreased daytime and nighttime frequency, incontinence and urgency appear more 
pronounced and persistent in the study by Kalsi [6] than in our series. Moreover, in our study the mean 
number of urgency episodes, and mean daytime and nighttime frequency showed a tendency to 
increase again after 12-week follow-up, although urgency episodes and daytime frequency remained 
significantly decreased compared to before treatment. Our follow-up was only until 12 weeks after 
treatment and the median interval after which patients requested re-injection was 8 months. This 
shows that from the patient viewpoint the effect of 100 units OnabotulinumtoxinA lasted for a period 
comparable to that in the study by Kalsi [6]. 
Our results show that intradetrusor injections of 100 units OnabotulinumtoxinA alleviated OABS 
significantly in our MS population. However, 100 units OnabotulinumtoxinA do not preserve initial 
detrusor contractility and cannot generally prevent the need for de novo ISC or even urinary diversion 
via a catheter. PVRV increased significantly, and mean Qmax and voided volume decreased, although 
not significantly. BoNT/A intradetrusor injections may most often cause a higher incidence of de novo 
ISC and increased PVRV in patients with neurogenic OABS but not or only rarely in those with 
NNOAB presumably due to the already neurologically compromised process of bladder emptying, e.g. 
DSD, in the neurogenic OABS population [6]. However, that observation may be biased or influenced 
by the use or omission of a certain PVRV threshold at which to start ISC as well as the potential 
difference of those thresholds among studies. A recent study using 200 units OnabotulinumtoxinA in 
patients with NNOAB showed quite a high number with de novo ISC with a PVRV threshold requiring 
ISC at 200 ml regardless of symptoms [14]. Thus, using or not using a PVRV threshold for ISC and its 
level can significantly influence the study outcome. In our series we did not use a fixed PVRV 
threshold for ISC but rather focused on symptomatology. 
To our knowledge there is yet no evidence-based consensus of PVRV threshold use, although experts 
on this topic from the United Kingdom seems to be ahead [15]. The suggested United Kingdom 
consensus of a 100 ml PVRV cutoff for ISC regardless of symptoms is straightforward and seems to 
be reasonable treatment since full functional bladder capacity is available in the storage phase due to 
complete bladder emptying by ISC [15]. Also, all patients in whom BoNT/A intradetrusor treatment is 
planned should be encouraged to learn ISC since increased PVRV or even urinary retention are 
known risk factors [7, 14, 16]. However, ISC done at least 4 to 6 times daily only because of a certain 
PVRV is not evidence-based and can be discussed critically. Moreover, it may not meet the individual 
expectations and needs of a patient with OAB. 
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In regard to this issue daily practice may legitimately differ from the protocol in prospective studies. To 
our knowledge no current study provides enough evidence to establish a certain PVRV threshold. A 
recent literature review stated that PVRV greater than 300 ml may be considered to favor UTI 
development [1]. Another group noted in a series of patients with stroke that PVRV greater than 150 
ml seems to be an independent risk factor for UTI [17]. None of our patients had PVRV greater than 
200 ml at 12-week follow-up or an increased incidence of UTI. Only 1 patient, who was 1 of the 2 
requiring ISC twice daily, had a PVRV of 350 ml. 
 
 
Figure 4 Three-day VD results in all patients at visits 1 (open bars), 4 (light gray bars) and 5 
(dark gray bars) regarding daytime (§ indicates p = 0.002 and # indicates p = 0.004) and 
nighttime (§ indicates p = 0.005) frequency, incontinence, urgency (§ indicates p = 0.013 and 
# indicates p = 0.008) and pad use (§ indicates p = 0.02 and # indicates p = 0.011). Box plots 
indicate minimum, 25% percentile, median, 75% percentile and maximum of 3-day averages. 
 
When OABS are satisfactorily treated, no recurrent UTI develops, no VUR is present and patients can 
still sufficiently empty the bladder without symptoms, it may be justified to omit or decrease the 
frequency of ISC. However, regular follow-up investigations remain mandatory since the 
consequences of sustained high PVRV on the UUT in this population have not yet been specifically 
assessed. In this context α-receptor-antagonists may be an option to decrease outflow resistance and, 
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thus, PVRV in these patients. In our study 100 units OnabotulinumtoxinA intradetrusor injections 
enabled most patients to omit or at least decrease ISC to a minimum without symptoms. 
Since OABS development and severity can be quite heterogeneous in the MS population [1], a more 
rational approach would be to first start at a low dose and increase the dose during the treatment 
course according to symptoms and the treatment effect, as it is usually done with most other forms of 
drug therapy. 
Potential limitations of this study are 1) our small number of patients, which is probably the cause of 
the high SD in some outcome parameters and the subsequent lack of significance, e.g. incontinence 
episodes, and 2) uroflowmetry and voiding diary follow-up was only up to 12 weeks, limiting 
information on the real duration of efficacy. Nevertheless, our pilot study presents promising first 
results of a different approach to OABS treatment in patients with MS and BoNT/A use in this context. 
 
CONCLUSIONS 
100 units OnabotulinumtoxinA seemed to be effective and safe for OABS in our MS study group due 
to significantly decreased urgency episodes, daytime and nighttime frequency, pad use and Pdetmax, 
and significantly increased MCC. However, initial detrusor contractility was not maintained since PVRV 
increased significantly and Qmax decreased. Nevertheless, most patients were able to remain on 
voluntary voiding without symptoms. The median time to when patients requested re-injection due to 
OABS relapse was 8 months. Results favour a treatment approach starting with a low BoNT/A dose 
with the possibility of increasing the dose, when applicable. This may be a reasonable OABS 
treatment in patients with MS who still void voluntarily.  
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